"Based at the Bergonié Institute, where it has access to a technology platform that is unique in Europe, Explicyte has been chosen by biotech company Cure51 to participate in the world's largest study aimed at analyzing the biological mechanisms of exceptional cancer survivors. The goal is to develop new treatments."
Read more
